<DOC>
	<DOCNO>NCT02962648</DOCNO>
	<brief_summary>Evaluation safety efficacy IV iron isomaltoside re-dosing .</brief_summary>
	<brief_title>An Extension Trial Assess Safety Re-dosing Iron Isomaltoside ( Monofer® )</brief_title>
	<detailed_description>Among various formulation parenteral iron available market , iron isomaltoside may allow flexibility term high rapid dosing . The use parenteral iron , especially high dos , may result good compliance , few visit medical practitioner , overall improvement QoL . Most trial IV iron 4-12 week trial long-term trial warrant fol-low-up long-term safety . This trial 6-months extension trial aim evaluate safety efficacy IV iron isomaltoside re-dosing .</detailed_description>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>1 . Completed one leadin trial 2 . Randomised dosed iron isomaltoside one leadin trial . 3 . Hb ≤ 10 g/dL 4 . Screening sferritin ≤ 100 ng/mL , ≤ 300 ng/mL TSAT≤ 30 % 5 . Willingness participate signing informed consent form ( ICF ) 1 . IV iron treatment leadin trial screen 2 . During 30day period prior screen trial period ; treat red blood cell transfusion , radiotherapy , and/or chemotherapy 3 . Received investigational drug within 30 day screen 4 . Decompensated liver cirrhosis active hepatitis 5 . Pregnant nursing woman . 6 . Any laboratory abnormality , medical condition , psychiatric disorder , opinion Investigator , put subject 's disease management risk may result subject unable comply trial requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>IDA</keyword>
</DOC>